HIGHLIGHTS
- who: Vincent T. Ma and collaborators from the Center, United States University of Alberta, Canada have published the Article: Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab, in the Journal: (JOURNAL)
- what: Although the trial was not designed to compare the nivolumab-containing cohorts, descriptive subgroup analyses showed superior PFS and OS with I/N compared to nivolumab alone . For this study, the authors applied the revised RECIST guideline (version 1.1) , with the noted exception of following the largest target lesions in retrospect, with assessments of complete response (CR), partial . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.